A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
Status:
RECRUITING
Trial end date:
2025-07-15
Target enrollment:
Participant gender:
Summary
A Phase 1, randomized, double-blind, placebo-controlled study of BMS-984923 administered orally twice daily (BID) for 28 days in participants with Parkinson's disease.
Phase:
PHASE1
Details
Lead Sponsor:
Allyx Therapeutics
Collaborator:
Michael J. Fox Foundation for Parkinson's Research